Sinobioway Medicine(002581.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Sinobioway Medicine
002581.SZ
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. The company is involved in the chemical raw materials, chemical product manufacturing, and biopharmaceutical manufacturing; production and sales of medicines. It also offers operating chemical products, such as trimethyl ester and triethyl ester.
3.143 T
002581.SZMarket value -Rank by Market Cap -/-

Financial Score

18/01/2026 Update
D
PharmaceuticalsIndustry
Industry Ranking197/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-11.15%D
    • Profit Margin-85.65%E
    • Gross Margin22.23%D
  • Growth ScoreD
    • Revenue YoY-36.54%E
    • Net Profit YoY36.48%B
    • Total Assets YoY-3.54%D
    • Net Assets YoY-9.61%D
  • Cash ScoreE
    • Cash Flow Margin-116.76%D
    • OCF YoY-36.54%E
  • Operating ScoreE
    • Turnover0.11E
  • Debt ScoreA
    • Gearing Ratio10.00%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sinobioway Medicine equity case second instance retrial: revocation of embezzlement charge, reduced prison term and fine

    The Intermediate People's Court of Zibo City made a second-instance judgment on the equity dispute case of Sinobioway Medicine, revoking the embezzlement charges against three defendants, with significant reductions in their sentences and fines. Pan Aihua was sentenced to five years for the crime of misappropriation of funds, Li Pengfei was sentenced to two years for the crime of forgery of official documents and one year for the crime of forgery of company seals, and Luo Deshun was sentenced to three years for the crime of misappropriation of funds. Pan Aihua is required to return 12.75 million yuan to Sinobioway Biomedicine Co., Ltd

    Wallstreetcn·
    SZ
    002581
    -3.10%
    Wallstreetcn·
    SZ
    002581
    -3.10%

    The flu vaccine has a "freezing point price" of 5.5 yuan

    In September, multiple provinces including Beijing and Zhejiang have successively launched this year's influenza vaccine vaccination work. A piece of news stating that "the unit price of the public-funded influenza vaccine has dropped to 5.5 yuan" has attracted industry attention. On September 1 and 2, the National Public Resources Trading Platform (Beijing) successively released the winning announcements for the 2025 Beijing influenza vaccine immunization and non-immunization procurement projects, with HUALAN BIOLOGICAL, Shanghai Institute of Biological Products, and Beijing Kexing being awarded the "immunization" project. (Yicai)

    36Kr·
    SZ
    002007
    -1.36%
    SZ
    002581
    -3.10%
    36Kr·
    SZ
    002007
    -1.36%
    SZ
    002581
    -3.10%

    Sinobioway Medicine: Net loss of 67.3027 million yuan in the first half of 2025

    ST Sinobioway Medicine announced that in the first half of 2025, operating revenue was 70.7715 million yuan, a year-on-year decrease of 66.42%. The net loss attributable to shareholders of the listed company was 67.3027 million yuan, compared to a net loss of 29.6149 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital using reserves

    Zhitong·
    SZ
    002581
    -3.10%
    Zhitong·
    SZ
    002581
    -3.10%

    Sinovac's combined hepatitis A and B vaccine, Beirlaifu, is re-registered for market launch

    Beijing Kexing Holdings Co., Ltd. subsidiary Beijing Kexing Biological Products Co., Ltd. independently developed the combined hepatitis A and B vaccine Beirlaifu, which has obtained the drug re-registration approval notice, making it the only combined hepatitis A and B vaccine approved for market in China

    Zhitong·
    SZ
    002581
    -3.10%
    Zhitong·
    SZ
    002581
    -3.10%

    ST Sinobioway Medicine: Tianjin Sinobioway is subject to other risk warnings

    ST Sinobioway Medicine announced that its controlling subsidiary, Tianjin Sinobioway Biomedical Co., Ltd., has been subjected to risk control measures that suspend production and sales, and it is expected that normal production and business activities cannot be resumed within three months. This triggers relevant provisions of the "Shenzhen Stock Exchange Stock Listing Rules." Starting from July 8, 2025, it will be subject to other risk warnings, and the stock abbreviation will be changed to "ST Sinobioway." The daily price fluctuation limit for stock trading will be 5%

    Zhitong·
    SZ
    002581
    -3.10%
    Zhitong·
    SZ
    002581
    -3.10%
    © 2026 Longbridge｜Disclaimer